ACS Offers Catalog of Hard-to-Find Products for Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

ATLANTA--The American Cancer Society is offering a "magalog," part magazine, part catalog, for women recovering from breast cancer and other cancers that involve treatment-related hair loss. Known as tlc (tender loving care), the nonprofit publication was created by Lana Leavitt Rosenfeld, an ACS volunteer.

ATLANTA--The American Cancer Society is offering a "magalog," part magazine, part catalog, for women recovering from breast cancer and other cancers that involve treatment-related hair loss. Known as tlc (tender loving care), the nonprofit publication was created by Lana Leavitt Rosenfeld, an ACS volunteer.

The catalog offers helpful articles on cancer-related issues and a wide selection of fashionable, hard-to-find products for women with cancer. The Fall/Winter 1998 edition, available in September, will offer a new selection of turbans and hats, including an exclusive line of turbans in ultra suede and panne velvet, and an expanded line of affordable lightweight wigs.

For the first time, tlc has designed a soft stretch sleep cap trimmed with lace and ribbons and appliquéd with butterflies, with matching lace-trimmed nightgown with pockets for prostheses. Also new this season, an exclusive T-shirt designed with a built-in bra to wear during radiation treatment and for leisure time.

The catalog offers a selection of pocketed camisoles and teddies as well as pocketed bras, silicone prostheses, and latex and foam breast forms. Other special products include a "hat sizer" to make regular-sized hats fit heads with little or no hair and a wig/cap liner to protect sensitive scalps from scratchy wigs or hats.

To receive a free copy of tlc, call 800-850-9445; fax 800-757-9997; write tlc at 340 Poplar St. Hanover, PA 17333, or order on the Internet at www.cancer.org. To ensure privacy, tlc is mailed only upon request, and customers’ names will not be provided to anyone for any purpose.

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content